Stock listing
IQT0 Stock Price, News, Filings & Events — Inhibikase Therapeutics, Inc.
Selected listing: IQT0 · GETTEX · EUR · DE
This page tracks Inhibikase Therapeutics, Inc.'s IQT0:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IQT0:GETTEX. IQT0:GETTEX is the stock-level entry point for investors researching Inhibikase Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- IQT0:GETTEX
- Asset type
- Stock
- Market cap
- $326.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- GETTEX
- Currency
- EUR
Inhibikase Therapeutics, Inc. IQT0:GETTEX stock context
This page tracks Inhibikase Therapeutics, Inc.'s IQT0:GETTEX listing on GETTEX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IQT0:GETTEX. IQT0:GETTEX is the stock-level entry point for investors researching Inhibikase Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
August 11, 2026
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
July 23, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility
July 15, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
July 14, 2026
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
May 12, 2026
Inhibikase Therapeutics, Inc. earnings calls
Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call
August 15, 2024 · Replay with transcript and chapters
Inhibikase Therapeutics, Inc. (IKT) Q1 2024 Earnings Call
May 16, 2024 · Replay with transcript and chapters
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call
March 28, 2024 · Replay with transcript and chapters
Inhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call
November 15, 2023 · Replay with transcript and chapters
Inhibikase Therapeutics, Inc. (IKT) Q2 2023 Earnings Call
August 15, 2023 · Replay with transcript and chapters
Inhibikase Therapeutics, Inc. (IKT) Q1 2023 Earnings Call
May 16, 2023 · Replay with transcript and chapters
Research Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for IQT0:GETTEX.
Inhibikase Therapeutics, Inc. company profile
View the public company page for Inhibikase Therapeutics, Inc. on 6ix.
Inhibikase Therapeutics, Inc. news
Read company news and market updates connected to Inhibikase Therapeutics, Inc..
Inhibikase Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Inhibikase Therapeutics, Inc..
Alternate listings
IKT:NASDAQ
US · USD
Alternate listing for Inhibikase Therapeutics, Inc.; the primary context on this page is IQT0:GETTEX.
IKT:BOATS
US · USD
Alternate listing for Inhibikase Therapeutics, Inc.; the primary context on this page is IQT0:GETTEX.
IQT0:MUN
DE · EUR
Alternate listing for Inhibikase Therapeutics, Inc.; the primary context on this page is IQT0:GETTEX.
IQT0:SWB
DE · EUR
Alternate listing for Inhibikase Therapeutics, Inc.; the primary context on this page is IQT0:GETTEX.